Entries |
Document | Title | Date |
20080214511 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists - The present invention is directed to compounds of Formula I: I (where A | 09-04-2008 |
20080269176 | New Salts - There is provided pharmaceutically-acceptable acid addition salts of compounds of formula (I), | 10-30-2008 |
20080275009 | ORAL ADMINISTRATION OF N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-1,3-THIAZOLE-5-CARBOXAMIDE AND SALTS THEREOF - Disclosed are a method of treating cancer and/or other proliferative diseases comprising orally administering N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof, and pharmaceutical compositions comprising N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof. Also disclosed are N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide salts, as well as crystalline forms thereof. | 11-06-2008 |
20080275010 | COMPOSITIONS AND METHODS TO PREVENT TOXICITY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS - Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed. The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs. | 11-06-2008 |
20080275011 | USE OF DIPYRIDAMOLE, ACETYLSALICYLIC ACID AND AN ANGIOTENSIN II ANTAGONIST FOR TREATMENT AND PREVENTION OF VASCULAR EVENTS - This invention relates to a method of treating and preventing vascular events and circulatory disorders in a patient in need thereof, especially in a patient at risk for said indications, using dipyridamole in combination with acetylsalicylic acid (ASA) and an angiotensin II antagonist, corresponding pharmaceutical compositions, and the use of dipyridamole for the manufacture of a corresponding pharmaceutical composition comprising a combination of dipyridamole, acetyl salicylic acid and an angiotensin II antagonist. | 11-06-2008 |
20080280857 | CGRP receptor antagonists - The present invention is directed to compounds of Formula I: | 11-13-2008 |
20090023691 | DELAYING THE AGEING PROCESS AND DISORDERS CAUSED BY AGEING - The present invention relates to the field of ageing, particularly to the prevention and/or treatment of ageing process and disorders caused by ageing and particularly to the prevention and/or treatment of atherosclerosis, neurodegenerative disorders and malignant diseases. A composition is provided, which comprises four or more active ingredients to reduce or suppress the ageing process or symptoms associated therewith. | 01-22-2009 |
20090036412 | Methods and Compositions for Inhibition of Angiogenesis - The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally. | 02-05-2009 |
20090042841 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS - This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD). | 02-12-2009 |
20090054380 | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection - The present invention relates to | 02-26-2009 |
20090062239 | THROMBIN RECEPTOR ANTAGONISTS AS PROPHYLAXIS TO COMPLICATIONS FROM CARDIOPULMONARY SURGERY - Disclosed herein are methods of preventing, inhibiting, or ameliorating complications associated with cardiopulmonary bypass surgery by the use of a thrombin receptor antagonist compound. Among the thrombin receptor antagonist compounds useful in these methods are those of Formulas I and II, described herein. Examples of such thrombin receptor antagonists include: | 03-05-2009 |
20090069275 | LOW FLUSH NIACIN FORMULATION - The invention relates to an extended-release matrix formulation capable of being directly compressed into tablets comprising niacin, a release-retarding agent, and other excipients. The resulting tablets of the invention demonstrate favorable release characteristics and a reduction in the severity, duration and incidences of cutaneous flushing commonly associated with niacin treatment. | 03-12-2009 |
20090075949 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases - The invention relates to a method of treating and preventing thromboembolic disorders, comprising administering dipyridamole in combination with an antithrombotic selected from direct thrombin inhibitors, factor Xa inhibitors and combined thrombin/factor Xa inhibitors to a patient, pharmaceutical compositions suitable for this method of treatment as well as the use of dipyridamole for the manufacture of these pharmaceutical compositions. | 03-19-2009 |
20090075950 | Dosage Forms Containing A PPI, NSAID And A Buffer - Provided herein, are dosage forms comprising an NSAID, a buffer and a PPI, as well as methods of treating various maladies using the above dosage form. | 03-19-2009 |
20090082315 | Compositions and Methods for Controlling Cholesterol Levels - New compositions and methods are provided for controlling cholesterol levels. The present compositions are uniquely structured to allow a subject to whom the compositions, in the form of unit dosage forms, are administered to benefit from both a statin, such as atorvastatin, and niacin. | 03-26-2009 |
20090105197 | Use of Sodium Channel Blocking Compounds and Aspirin in Manufacturing Drugs for Producing Analgesia Synergistically in Mammals - This invention relates to the use of combinations of a sodium channel blocking compound that binds to an SSI or SS2 site of extracellular region of a sodium channel alpha subunit, and aspirin in manufacturing drugs for producing synergistically analgesic effect in mammals. Pharmaceutical compositions based upon this invention can enhance analgesic effect and reduce dosage of aspirin, therefore side effects and adverse reactions are decreased accordingly. | 04-23-2009 |
20090137535 | Substituted oxazolidinone derivatives - This invention relates to novel compounds that are substituted oxazolidinones derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel oxazolidinones compounds that are derivatives of rivaroxaban. The invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and condition that are beneficially treated by administering a selective inhibitor of factor Xa, such as rivaroxaban. | 05-28-2009 |
20090143341 | MICROBICIDAL COMPOSITION - The invention relates to a microbicidal composition which comprises a mixture of at least two components, the first component being 2-methyl-3-isothiazolone (MIT) and the second component being at least one active compound selected from the following groups of active compounds: a) compound having activated methylol groups b) quats or polyquats c) carbamates d) organic acids e) aromatic alcohols. | 06-04-2009 |
20090163450 | COMBINATIONS COMPRISING A PROSTAGLANDIN AND USES THEREOF - The invention relates to a combination comprising (a) a compound selected from the class of prostaglandins and (b) a compound selected from the class of tubulin/microtubule interfering agents and/or (c) a compound selected from the class of cyclooxygenase inhibitors. | 06-25-2009 |
20090192123 | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of Thrombin and/or by elevated expression of Thrombin receptors - A method of treatment of the human or non-human animal body for treating or preventing disorders caused by elevated thrombin or elevated thrombin receptor expression is disclosed, for example thromboembolic disease vascular syndromes, or proliferative diseases, which method comprises administering to a human or non-human animal body in need of such treatment an effective amount of a pharmaceutical composition containing dipyridamole, mopidamole or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions as well as the use of dipyridamole or mopidamole for the manufacture of these pharmaceutical compositions. | 07-30-2009 |
20090221535 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE - The present invention is directed to compounds of Formula I: I (where A | 09-03-2009 |
20090258843 | Compositions Containing Antiviral Compounds and Methods of Using the Same - The present invention is directed to compositions and methods for the treatment of various diseases, pathological disorders, and medical conditions such as viral infections and cancer. The compositions include (A) an antiviral compound or a pharmaceutically acceptable salt thereof; and (B) an agent selected from the group consisting of a substituted or unsubstituted imidazole or a pharmaceutically acceptable salt thereof; a non-steroidal anti-inflammatory agent or a pharmaceutically acceptable salt thereof; an amino acid or a pharmaceutically acceptable salt thereof; a carboxylic acid or a pharmaceutically acceptable salt thereof; a sulfonic acid or a pharmaceutically acceptable salt thereof; and a combination thereof. | 10-15-2009 |
20090298797 | COMBINATION THERAPY FOR THE TREATMENT OF INFLUENZA - Compositions and methods for treating one or more symptoms of influenza, preferably influenza due to infection with influenza A (H5N1) are provided. It has been discovered that administration of a combination of a neuraminidase inhibitor with two immunomodulators increases survivability in subjects 24, 48, or even 72 hours post infection compared to administration of the neuraminidase inhibitor alone. A preferred neuraminidase inhibitor is zanamivir. Preferred immunomodulators include, but are not limited to celecoxib and mesalazine. Another embodiment provides a method for treating influenza, preferably, influenza due to infection with avian influenza A (H5N1) by administering to subject infected with the influenza virus, an effective amount of a neuraminidase inhibitor to inhibit or reduce budding of the influenza virus from infected cells of the subject, and an effective amount of at least two immunomodulators effective to reduce or inhibit one or more symptoms of inflammation in the subject. | 12-03-2009 |
20090306024 | Combination preparations of o-acetylsalicylic acid salts - The present invention relates to a fixed combination comprising a salt of o-acetylsalicylic acid with a basic amino acid as component A and an HMG-CoA reductase inhibitor as component B, a medicament comprising this combination and a process for its production. | 12-10-2009 |
20090306025 | Method and composition for skin inflammation and discoloration - The invention provides a method and compound for treating darkness and/or swelling/inflammation of the skin of humans. An antihistamine compound and a non-steroidal anti-inflammatory drug (NSAID) compound in combination have been found to effectively treat under eye darkness, swelling and puffiness in particular, when applied topically to the affected skin. | 12-10-2009 |
20100022484 | 4-Chromenonyl-1,4-dihydropyridines and their use - The present application relates to novel 4-chromenonyl-1,4-dihydropyridines, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders. | 01-28-2010 |
20100035848 | THERAPY FOR DISORDERS OF THE PROXIMAL DIGESTIVE TRACT - A method for managing or treating an inflammatory, erosive, dyspeptic or reflux disorder of the proximal digestive tract of a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor. A therapeutic combination, useful to treat any disease or condition in which an NSAID is indicated, comprises an NSAID in an anti-inflammatory, analgesic or antipyretic effective amount and a gastroprotective agent that comprises an ACE2 inhibitor in an amount effective to protect mucosal surfaces of the proximal digestive tract from erosion or ulceration induced by the NSAID. | 02-11-2010 |
20100035849 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE - The present invention provides novel methylenedioxy phenolic compounds and their derivatives, methods of making them and methods of using them to treat or prevent cardiovascular disease, vascular disease and/or inflammatory disease, as well as Type I and Type II Diabetes and Dyslipidemia patients at risk for hypertension, stroke, cardiovascular and renal disease. | 02-11-2010 |
20100048518 | Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent - The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition comprises a combination of tenatoprazole and one or more anti-inflammatory agents selected from non-steroid anti-inflammatory agents and cyclooxygenase-2 inhibitors. The invention is suitable for the treatment of painful and inflammatory manifestations. | 02-25-2010 |
20100075931 | Substituted oxazole ketone modulators of fatty acid amide hydrolase - Certain oxazole ketone compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). | 03-25-2010 |
20100130453 | USE OF FOLATES FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASES - This invention relates to the use of folates for the prevention and/or treatment of cardiovascular diseases, such as atherosclerosis, and in particular for modulating endothelial nitric oxide synthase (eNOS). The invention further relates to pharmaceutical preparations consisting of said folates and a pharmaceutically acceptable carrier, optionally in combination with other pharmaceutically active agents, as well as therapeutic methods using said folates or pharmaceutical preparations thereof. | 05-27-2010 |
20100160266 | ORGANIC COMPOUNDS - A pleuromutilin in the form of a salt with salicylic acid, azelaic acid, sebacic acid or 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid. | 06-24-2010 |
20100184727 | TREATMENT OF EXCESS SEBUM PRODUCTION - A muscarinic receptor antagonist is useful for the treatment or prevention of a condition associated with excess sebum production or excretion. | 07-22-2010 |
20100184728 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS - The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient. In another embodiment, compounds or compositions are orally administered. The subject invention also concerns methods for screening for, assessing risk of developing, and/or diagnosing conditions associated with oxidative stress, such as ulcerative colitis and other inflammatory bowel disorders. | 07-22-2010 |
20100184729 | New Pharmaceutical Compositions for Treatment of Thrombosis - The present invention relates to novel pharmaceutical compositions comprising at least one direct thrombin inhibitor and at least one additional active compound selected from the groups consisting of platelet inhibitors, low molecular weight heparins (LMWH) and heparinoids as well as unfractionated heparin, factor X | 07-22-2010 |
20100210605 | Compositions Comprising 5-Amino-2-Hydroxybenzoic Acid and a Reducing Sugar - Compositions comprising 5-amino-2-hydroxybenzoic acid (5-amino salicylic acid, mesalamine) and a reducing sugar, e.g., lactose, undergo the Maillard and other chemical reactions and produce, in the case of lactose, a degradant 5-[2-formyl-5-(hydroxymethyl)-1H-pyrrol-1-yl]-2-hydroxybenzoic acid. Inventors have developed means to contain and/or reduce the formation of degradants of 5-amino-2-hydroxybenzoic acid. | 08-19-2010 |
20100210606 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The invention features a method for treating an immunoinflammatory administering a compound of formula (I), e.g., ibudilast or KC-764, alone or in combination with a corticosteroid, tetra-substituted pyrimidopyrimidine, or other compound. The invention also features pharmaceutical compositions including the combination above for the treatment or prevention of an immunoinflammatory disorder. | 08-19-2010 |
20100240620 | 3-Cyano-5-thiazaheteroaryl-dihydropyridine and the use thereof for the treatment of cardiovascular diseases - The present application relates to novel aryl-substituted 3-cyano-5-thiazolyl- and 3-cyano-5-thiadiazolyl-1,4-dihydropyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders. | 09-23-2010 |
20100249078 | TETRACYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE - Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). | 09-30-2010 |
20100249079 | ANALOGUES OF CILOSTAZOL - This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol. | 09-30-2010 |
20100261684 | Pharmaceutical combination of medication to be used by patients presenting with an acute coronary syndrome so as to stop the process and prevent a myocardial infarction - As many as 60% of patients who experience an acute coronary syndrome die before they even reach a hospital or other health care facilities, hence the importance of an effective treatment that the patient can self-administer at the first symptom or sign of an acute coronary syndrome. That treatment needs to act rapidly, to be easy to use, to be effective, to be safe, and readily available. The present invention describes a pharmaceutical combination containing a beta blocker agent, one or more anti-platelet agent(s) and a coronary vaso-dilator agent all included in a dose format to be taken orally or by sublingual spray to prevent myocardial infarction. | 10-14-2010 |
20100261685 | PERSONAL CARE COMPOSITION - A personal care composition comprising a eutectic mixture, the eutectic mixture comprising a tertiary system, in which menthol may form part of the eutectic mixture or in the eutectic mixture comprises an antidandruff agent such as ketoconazole. | 10-14-2010 |
20100273746 | PHARMACEUTICAL FORMULATIONS CONTAINING TOLPERISONE - The present invention relates to pharmaceutical formulation containing tolperisone or its pharmaceutically acceptable salts or tolperisone combined with a non-steroidal anti-inflammatory drug or their salts, gel forming macromolecule, solvent, and if required thickening agent, penetration enhancer and pH adjuvant or the mixture thereof. The invention also relates to the manufacturing process of the above mentioned pharmaceutical compositions, further the use of these formulations and the containers suitable for the dosage, which are dual compartment containers consisting of two separated chambers. | 10-28-2010 |
20100279987 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF - The present invention features composition comprising a chalcone and the use thereof for treating acne and reducing the appearance of oil or pores on the skin, hair and scalp. | 11-04-2010 |
20100286098 | USE OF TETRAHYDROCANNABINOL AND/OR CANNABIDIOL FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease. | 11-11-2010 |
20100305074 | NIACIN-BASED PHARMACEUTICAL COMPOSITIONS - The disclosure relates generally to niacin-based pharmaceutical compositions that include at least one pharmaceutical agent capable of treating a niacin-induced side-effect. Accordingly, one aspect of this disclosure is a pharmaceutical composition for delivering niacin to a patient in need thereof, wherein the composition comprises a therapeutic dose of niacin and a therapeutically effective dose of at least one pharmaceutical agent capable of reducing an adverse side-effect of niacin in the patient, and wherein the pharmaceutical agent is delivered to the patient jointly with the niacin, preferably as a single dosage pill or tablet. | 12-02-2010 |
20100305075 | COMPOSITION AND METHOD OF TREATING HEARING LOSS - A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is greater than the effect of the individual components alone. The composition includes a biologically effective amount of vitamin E for inhibiting propagation of lipid peroxidation that contributes to hearing loss. The composition also includes a biologically effective amount of a salicylate for reducing hydroxyl radicals that contribute to hearing loss. A method of treating hearing loss includes the step of internally administering the composition, as described above, to a mammal within three days of trauma to a middle or inner ear of the mammal. In other words, the composition is effective even when administered as late as three days after trauma to a middle or inner ear of a mammal. | 12-02-2010 |
20100311700 | Transdermal preparation for external use containing nonsterioidal antiinflammatory/analgesic agent - A transdermal preparation for external use which contains a photosensitive NSAID and a UV blocker having a high ability to migrate into the skin. Thus, it becomes possible to ensure, in a transdermal preparation for external use containing a NSAID, the inhibition of the onset of light-induced non-immunological or immunological skin symptoms by the above-described component. | 12-09-2010 |
20110034424 | METHOD FOR THE LONG TERM NSAID USE - Provided is a method for the long term treatment of a condition or disease which is one of the indications for NSAID use in a human patient, which comprises administering to the patient a pharmaceutically effective amount of a NSAID and at least 36 mcg per day of cobiprostone or its pharmaceutically acceptable salt, ester, ether or amide. By administering cobiprostone or its pharmaceutically acceptable salt, ester, ether or amide in combination with a NSAID, the patient can receive the NSAID for longer time period. | 02-10-2011 |
20110065676 | COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH NAR AGONISTS - The present invention is directed to a pharmaceutical composition comprising an effective amount of at least one PAR1 antagonist, at least one NAR agonist, optionally, an effective amount of at least one cardiovascular agent, and, optionally, a pharmaceutically acceptable carrier. The present invention also provides for the use of theses pharmaceutical compositions to treat various diseases associated with thrombosis. | 03-17-2011 |
20110071117 | COMBINATIONS OF ANTIOXIDANTS AND ANTI-INFLAMMATORY DRUGS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - Disclosed herein are compositions comprising 5-aminosalicylic acid (5-ASA), or a pharmaceutically acceptable salt thereof and an antioxidant, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating an inflammatory bowel disease in a subject, reducing cytokine gene expression in colonic tissue of a subject, and reducing myeloperoxide activity in colonic tissue of a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising 5-ASA, or a pharmaceutically acceptable salt thereof, and an antioxidant, or a pharmaceutically acceptable salt thereof. | 03-24-2011 |
20110082118 | Onychomycosis Treatment Delivery System - A topical treatment for onychomycosis and Tinea pedis comprising a delivery system further comprising at least one hydroxy acid agent having a pH-pKa value of 0.5 or greater and at least one antifungal agent formulated into creams, lotions, gels, sprays, foams, pads, films, patches, and solutions. | 04-07-2011 |
20110105441 | Stable Orally Disintegrating Tablets Having Low Superdisintegrant - The invention is directed to the functionality and performance of superdisintegrants in orally disintegrating tablets (ODT). The invention can be an aged direct compression ODT having between about 0.3% to about 2% (wt/wt) sodium croscarmellose relative to the total weight of the ODT, a polyol matrix, optionally a lubricant, and an active pharmaceutical or nutraceutical ingredient, in which after storage for four months the ODT has a disintegration time using an excess water test that is less than 30 seconds and a tensile strength greater than 0.5 MPa. The invention is also directed to a direct compression ODT, consisting essentially of about 0.5% to 2.0% sodium croscarmellose, from 0.1% to 2.0% lubricant, an API, up to 10% (wt/wt) microcrystalline cellulose, optionally one or more colorants, sweeteners, fragrances, flavor compounds, and/or flavor blockers, and the balance spray-dried mannitol. | 05-05-2011 |
20110136767 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF - A series of monoquarternary piperazium salts including a structure of a formula I or II are provided. In formula I or II, R | 06-09-2011 |
20110183946 | Complexes Comprising alpha2-Adrenergic Receptor Agonists and Methods of Providing Neuroprotection or Treating or Inhibiting Progression of Glaucoma - A complex comprises at least an α | 07-28-2011 |
20110245209 | PYRIDOPYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Pyridopyrimidine Derivatives of formula (I), compositions comprising a Pyridopyrimidine Derivative and methods for using the Pyridopyrimidine Derivatives for treating or preventing a metabolic disorder, dyslipidemia, a cardiovascular disease, a neurological disorder, a hematological disease, cancer, inflammation, a respiratory disease, a gastroenterological disease, diabetes, a diabetic complication, obesity, an obesity-related disorder or non-alcoholic fatty liver disease. | 10-06-2011 |
20110245210 | THALIDOMIDE ANALOGS - Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs. | 10-06-2011 |
20110251160 | METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY - A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient a dosage of >150 mg b.i.d. to 300 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof. | 10-13-2011 |
20110263545 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS - The present invention provides hepatoprotectant acetaminophen mutual prodrugs, which have an acetaminophen moiety covalently linked to a second moiety that may act as a hepatoprotectant against acetaminophen hepatotoxicity. Additionally, acetaminophen mutual prodrugs may have improved water solubility which may provide better suitability for parenteral and other dosage forms relative to administration of acetaminophen. Also provided are methods of treating a disease or condition that is responsive to acetaminophen (such as fever, pain and ischemic injury) using hepatoprotectant acetaminophen mutual prodrugs, as well as kits and unit dosages. | 10-27-2011 |
20110269724 | Combination Therapy with Non-Selective COX Inhibitors to Prevent COX-Related Gastric Injuries - The present invention is directed to nicotinamide, nicotinamide derivatives and prostaglandin mimetics, alone or in combination with an NSAID, and their use in treating pain, inflammation, and/or gastrointestinal toxicty, | 11-03-2011 |
20110281828 | SUBSTITUTED OXAZOLIDINONE DERIVATIVES - This invention relates to novel compounds that are substituted oxazolidinones derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel oxazolidinones compounds that are derivatives of rivaroxaban. The invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and condition that are beneficially treated by administering a selective inhibitor of factor Xa, such as rivaroxaban. | 11-17-2011 |
20110294763 | TRANSDERMAL DELIVERY OF DICOLFENAC, CARBAMAZEPINE AND BENZYDAMINE - The invention discloses solutions of diclofenac, carbamazepine and benzydamine, at therapeutically desirable concentrations and the solutions stable for extended periods of time at room temperature. | 12-01-2011 |
20110301130 | TOPICAL COMPOSITION FOR THE TREATMENT OF ACTINIC KERATOSIS - The invention relates to a topical gel composition for use in the treatment of actinic keratosis comprising (a) an active agent for treatment of actinic keratosis, (b) a keratolytically active agent, (c) a gel former, and (d) an organic solvent. | 12-08-2011 |
20120028931 | HETEROCYCLIC M-GLU5 ANTAGONISTS - Compounds I | 02-02-2012 |
20120028932 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS - The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. | 02-02-2012 |
20120035143 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS - The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. | 02-09-2012 |
20120077783 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS - The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. The subject invention also concerns compositions formulated for oral administration. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient. In another embodiment, compounds or compositions are orally administered. | 03-29-2012 |
20120083476 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE - Certain heteroaryl-substituted spirocyclic diamine urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). | 04-05-2012 |
20120088740 | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - The invention relates to compositions and co-crystals each comprising VX-950 and a co-crystal former selected from the group consisting of salicylic acid, 4-amino salicylic acid, and oxalic acid. Also within the scope of this invention are methods of making and using the same. | 04-12-2012 |
20120088741 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE - Certain aryl-substituted heterocyclic urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). | 04-12-2012 |
20120088742 | ACETYLSALICYLIC ACID SALTS - Novel betaine salts of acetylsalicylic acid, namely 4-trimethylammoniobutanoate acetylsalicylic acid addition salt (gamma-butyrobetaine acetylsalicylate), L-carnitine acetylsalicylic acid addition salt and 3-(trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt. Use of meldonium acetylsalicylate as antiplatelet agent for treating various pathologies induced by platelet aggregation, anti-inflammatory and antihyperlipidemic agent. | 04-12-2012 |
20120108553 | Combination Therapy with Non-Selective COX Inhibitors to Prevent COX-Related Gastric Injuries - The present invention is directed to nicotinamide, nicotinamide derivatives and prostaglandin mimetics, alone or in combination with an NSAID, and their use in treating pain, inflammation, and/or gastrointestinal toxicty, | 05-03-2012 |
20120115822 | USE OF 5H-DIBENZ/B,F/AZEPINE-5-CARBOXAMIDE DERIVATIVES IN THE TREATMENT OF NEUROPATHIC PAIN AND NEUROLOGICAL DISORDERS - This invention relates to the use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives in the manufacture of various medicaments for treating neuropathic pain and for treating neurological disorders which involve both motor impairment and neuropathic pain. | 05-10-2012 |
20120157415 | New Crystalline Form of Pemirolast - There is provided a hemihydrate form of the sodium salt of pemirolast. | 06-21-2012 |
20120178724 | Compositions for Reducing the Incidence of Drug Induced Arrhythmia - In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and/or a statin. In certain embodiments, the compositions and methods for treatment comprise azimilide and aspirin and/or a statin. These compositions may be administered by different routes, including orally. In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg to about 300 mg. | 07-12-2012 |
20120232041 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ANGINA OR MYOCARDIAL INFARCTION INDUCED BY MYOCARDIAL ISCHEMIA - The present invention provides a pharmaceutical composition for the treatment and prophylaxis of angina and myocardial infarction, wherein a combination of a tea extract (catechins) and an antianginal drug are proved therapeutically potent in treating angina and mycocardial infarction induced from myocardial ischemia. The present invention also provides a use of a tea extract (catechins) in treating and preventing angina. | 09-13-2012 |
20120252765 | USE OF IRBESARTAN FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION OF HOSPITALIZATION FOR HEART FAILURE - Use of irbesartan or one of its pharmaceutically acceptable salts for the preparation of a medicament for the prevention of hospitalization for heart failure. | 10-04-2012 |
20120252766 | CO-CRYSTAL OF 4-FURAN-2(5H)-ONE WITH SALICYLIC ACID AND USE THEREOF AS PESTICIDE - The invention relates to a new co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one (I) with salicylic acid, and also to processes for preparation thereof and use thereof. | 10-04-2012 |
20120264721 | ANALOGUES OF CILOSTAZOL - This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of an phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol. | 10-18-2012 |
20120283226 | Cosmetic Composition - A dermatological or cosmetic composition for skin care which includes the salt of an α-hydroxy acid, β-hydroxy acid, poly hydroxy acid or bionic acid in combination with niacinamide. | 11-08-2012 |
20120316140 | ANALGESIC COMPOSITION AND METHOD OF MAKING THE SAME - A soluble aspirin composition, comprising: (i) granules including aspirin, heat-treated bicarbonate salt, pharmaceutically-acceptable resin and surfactant, in mixture with: (ii) crystalline particles of pharmaceutically-acceptable acid; and (iii) crystalline particles of heat-treated bicarbonate salt; wherein the soluble aspirin composition when introduced to water undergoes reaction of the crystalline particles of pharmaceutically-acceptable acid with the heat-treated bicarbonate salt and the aspirin to effect effervescing action and disintegration of the granules with conversion of the aspirin to an acetylsalicylate compound of the bicarbonate salt cation so that the composition rapidly dissolves in the water without occurrence of undissolved residue. The composition is solublizable within 30 seconds in cool to cold water to provide an effervescent analgesic solution that can be readily orally administered to an individual in need of analgesia. | 12-13-2012 |
20120322772 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES - The present application relates to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing. | 12-20-2012 |
20120329762 | ANTI-THROMBOTIC COMPOUNDS - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 12-27-2012 |
20120329763 | ANTI-THROMBOTIC COMPOUNDS - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 12-27-2012 |
20130018020 | INHIBITOR FOR MELANIN, AND COSMETIC COMPOSITION CONTAINING SAMEAANM Shin; Hong JuAACI Seongnam-siAACO KRAAGP Shin; Hong Ju Seongnam-si KRAANM Kim; Do HoonAACI SeoulAACO KRAAGP Kim; Do Hoon Seoul KRAANM Kim; Jeong HwanAACI Paju-siAACO KRAAGP Kim; Jeong Hwan Paju-si KRAANM Koh; Hyun JuAACI Anyang-siAACO KRAAGP Koh; Hyun Ju Anyang-si KRAANM Park; Won SeokAACI SeoulAACO KRAAGP Park; Won Seok Seoul KR - The present invention relates to a melanin production inhibitor containing, as active ingredients, tranexamic acid and nicotinic acid amide, which inhibits the formation of skin melanocytes, and to a cosmetic composition which contains the melanin production inhibitor as an active ingredient and has the effects of reducing liver spots, blemishes, freckles and post-inflammatory hyperpigmentation, improving skin tone and texture and whitening the skin. | 01-17-2013 |
20130023500 | CHONDROPSIN-CLASS ANTITUMOR V-ATPASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - A composition comprising a substantially purified compound of the formula: | 01-24-2013 |
20130035316 | PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND ROSUVASTATIN - This invention relates to the oral pharmaceutical composition of metformin and rosuvastatin. In detail, this invention comprising metformin, rosuvastatin, sustained release carriers and/or excipients reduces the side effects caused by statins and enhances safety, patients' convenience and compliance with its one-per-day dosage. In addition, regulation of an early effective blood concentration of the drug and maintenance of the drug's concentration at a steady level in vivo by a controlled-release can be advantageously used as a pharmaceutical composition for preventing and treating hyperlipidemia. | 02-07-2013 |
20130109661 | IMIDAZOPYRIDAZINE COMPOUNDS | 05-02-2013 |
20130131021 | ANALOGUES OF CILOSTAZOL - This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol. | 05-23-2013 |
20130157986 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE - Pharmaceutical compounds and compositions are provided which are methylenedioxy phenolic compounds and their derivatives, along with methods of making them and methods of using them for therapeutic purposes. The compounds and compositions are advantageous in that they can be used to treat or prevent cardiovascular disease, vascular disease and/or inflammatory disease, as well as Type I and Type II Diabetes and Dyslipidemia patients at risk for hypertension, stroke, cardiovascular and renal disease. | 06-20-2013 |
20130190276 | USE OF 5-H-DIBENZ/B,F/AZEPINE-5-CARBOXAMIDE DERIVATIVES IN THE TREATMENT OF NEUROPATHIC PAIN AND NEUROLOGICAL DISORDERS - This invention relates to the use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives in the manufacture of various medicaments for treating neuropathic pain and for treating neurological disorders which involve both motor impairment and neuropathic pain. | 07-25-2013 |
20130225537 | METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT - The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions. | 08-29-2013 |
20130237504 | Pharmaceutical Forms and Methods for Designing the Same - Methods for selecting active principles to be used in association within a single pharmaceutical form, the method comprising searching, selecting and analyzing published bibliographic data. The disclosure also relates computer-implemented methods for selecting active principles to be used in association within a single pharmaceutical form, comprising: selecting with a processor-implemented process at least one listing of keywords stored in memory; and submitting the keywords in a query. Further, the specification relates to pharmaceutical oral forms defined by implementing these methods, wherein at least two active principles are brought together in a leak proof water-soluble wrapping or envelop and the active principles cannot come into contact with one another. | 09-12-2013 |
20130289005 | Acne Vulgaris Treatment Regimen - A kit for treatment of acne vulgaris, said formulation of the kit effectively inhibiting or killing | 10-31-2013 |
20130316986 | Anti-Thrombotic Compounds - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 11-28-2013 |
20130316987 | Anti-Thrombotic Compounds - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 11-28-2013 |
20130338121 | TWO SPEED MONOLITHIC SYSTEM FOR CONTROLLED RELEASE OF DRUGS - The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process. | 12-19-2013 |
20130345182 | STABLE COMPOSITION COMPRISING CHOLESTEROL-LOWERING AGENTS, ANTIHYPERTENSIVE AGENTS AND ANTIPLATLET AGENTS - The present invention relates to a stable composition for providing substances with different types of activity, such as cholesterol lowering agents, antihypertensive agents and antiplatelet agents, which substantially reduce the dosage required to prevent cardiovascular events. | 12-26-2013 |
20140031320 | Anti-Thrombotic Compounds - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 01-30-2014 |
20140038924 | Anti-Thrombotic Compounds - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 02-06-2014 |
20140045800 | TETRACYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE - Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). | 02-13-2014 |
20140066412 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE - Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis). | 03-06-2014 |
20140066413 | ANALGESIC COMPOSITION AND METHOD OF MAKING THE SAME - A soluble aspirin composition, comprising: (i) granules including aspirin, heat-treated bicarbonate salt, pharmaceutically-acceptable resin and surfactant, in mixture with: (ii) crystalline particles of pharmaceutically-acceptable acid; and (iii) crystalline particles of heat-treated bicarbonate salt; wherein the soluble aspirin composition when introduced to water undergoes reaction of the crystalline particles of pharmaceutically-acceptable acid with the heat-treated bicarbonate salt and the aspirin to effect effervescing action and disintegration of the granules with conversion of the aspirin to an acetylsalicylate compound of the bicarbonate salt cation so that the composition rapidly dissolves in the water without occurrence of undissolved residue. The composition is solubilizable within 30 seconds in cool to cold water to provide an effervescent analgesic solution that can be readily orally administered to an individual in need of analgesia. | 03-06-2014 |
20140094438 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN - The claimed invention relates to compositions that may be in a form of a liquid, solid, gel, cream or gel capsule comprising an analgesic, and methods for administering these compositions for treatment of patients suffering from various forms of pain. | 04-03-2014 |
20140128353 | Solid Solution Compositions and Use in Cardiovascular Disease - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. | 05-08-2014 |
20140162987 | Solid Solution Compositions and Use in Severe Pain - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions. | 06-12-2014 |
20140179642 | Collagen Stimulators and Their Use in the Treatment of Skin - Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ cosmetic composition comprising novel active agents that enhance collagen production in the skin. | 06-26-2014 |
20140187517 | METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT - The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions. | 07-03-2014 |
20140221322 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE - Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis). | 08-07-2014 |
20140288028 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR - The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I. | 09-25-2014 |
20140329781 | METHODS FOR TREATING CARDIOVASCULAR DISORDER - The present invention relates to a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more antiplatelet agent along with one or more rate controlling excipients. | 11-06-2014 |
20150025046 | PREPARATION AND USE OF BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS - The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: X is —O—, —N(R), —C(R | 01-22-2015 |
20150045332 | Novel Sphingosine 1-Phosphate Receptor Antagonists - The present invention relates to sphingosine-1-phosphate (S1P) receptors and compounds of the general formula: | 02-12-2015 |
20150094285 | PHYTOCHEMICAL COMPOSITIONS INCLUDING SESAMIN FOR ANTI-INFLAMMATORY, ANTI-CYTOKINE STORM, AND OTHER USES - A composition (e.g., phytochemical composition) including sesamin, the composition exhibiting anti-inflammatory, anti-cytokine storm, connective tissue preservation, anti-viral, and/or other properties in biological tissue. The phytochemical composition therapeutically affects a pro-inflammatory cytokine condition, for instance facilitating or effectuating decrease in a quantity of a pro-inflammatory cytokine, for example, interleukin-1 and tumor necrosis-alpha. The phytochemical composition facilitates or effectuates an increase in quantity of an anti-inflammatory cytokines. The phytochemical composition can additionally facilitate a connective tissue extracellular matrix (ECM) preservation effect. The phytochemical composition can also inhibit an action of a viral neuraminidase, for example, the influenza A virus neuraminidase. Uses of sesamin for manufacture of phytochemical compositions having predetermined concentrations of sesamin include facilitating a decrease in quantity of pro-inflammatory cytokines, an increase in anti-inflammatory cytokines, a connective tissue anti-degenerative effect, and/or an inhibition of viral neuraminidase within the living organism. Manufacturing processes for the phytochemical compositions are also described. | 04-02-2015 |
20150105356 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS - The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient. In another embodiment, compounds or compositions are orally administered. The subject invention also concerns methods for screening for, assessing risk of developing, and/or diagnosing conditions associated with oxidative stress, such as ulcerative colitis and other inflammatory bowel disorders. | 04-16-2015 |
20150126479 | AQUEOUS SOLUTIONS OF 1,2-BENZISOTHIAZOLIN-3-ONE - What is described herein is an environment-friendly, highly aqueous solution of 1,2-benzisothiazolin-3-one (BIT) which is free from volatile organic compounds (VOC's), glycols, derivatives of glycols, glycerols and/or derivatives of glycerols. The composition comprises: (i) about 0.1% to about 30% by wt. of BIT; (ii) about 5% to about 15% by wt. of neutralizing agent; (iii) about 50% to about 85% by wt. of water; and (iv) about 0.1% to about 5% by wt. of chelating agent. The aqueous solution of BIT may further comprise at least one water soluble form of a co-biocide. The composition is efficient in protecting aqueous media against microbial attack in various industrial applications. | 05-07-2015 |
20150148319 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 05-28-2015 |
20150313910 | USE OF 5H-DIBENZ/B,F/AZEPINE-5-CARBOXAMIDE DERIVATIVES IN THE TREATMENT OF NEUROPATHIC PAIN AND NEUROLOGICAL DISORDERS - This invention relates to the use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives in the manufacture of various medicaments for treating neuropathic pain and for treating neurological disorders which involve both motor impairment and neuropathic pain. | 11-05-2015 |
20150313920 | METHODS FOR MAKING ACTIVE CRYSTALLINE MATERIALS - The present invention relates to an active crystalline material, especially an active multicomponent crystalline material such as a salt or a cocrystal, which may be made by dispersing precursor components of the active crystalline material in a liquid medium which comprises an anti-solvent, maintaining the dispersion for a period during which the active crystalline material is formed, and, during said period, exposing the dispersion to a solvent, which solvent being present in the liquid medium in a minor proportion by weight thereof. | 11-05-2015 |
20150328323 | Nitric Oxide Releasing Produgs of Therapeutic Agents - The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents wherein the drug or therapeutic agents contain at least one carboxylic acid group. The invention also relates to processes for the preparation of these nitric oxide releasing prodrugs, to pharmaceutical compositions containing them and to methods of using these produgs. | 11-19-2015 |
20160122307 | PERHYDROQUINOXALINE DERIVATIVES - The present invention relates to perhydroquinoxaline compounds according to the general formula (1), their use as a medicament, in particular as analgesic, antipruritic and anti-inflammatory agents, and their preparation. | 05-05-2016 |
20160143848 | NEAT LIQUID PHARMACEUTICAL FORMULATIONS - Essentially non-aqueous liquid pharmaceutical formulations are formed by mixing at least one pharmaceutically active ingredient and at least one other compound capable of interacting with the active pharmaceutical ingredient through non-covalent interactions to form a low-temperature transition mixture. The stable liquid formulations are readily obtained, even with drugs that are poorly soluble and/or unstable in water. | 05-26-2016 |
20160151277 | Pharmaceutical Formulation Containing Gelling Agent | 06-02-2016 |
20160200713 | PREPARATION AND USE OF 3-PYRIDYL SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS | 07-14-2016 |
20160200715 | PREPARATION AND USE OF 7A-HETEROCYCLE SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS | 07-14-2016 |
20160250217 | CRYSTALLINE FORM OF PEMIROLAST | 09-01-2016 |
20170232009 | Methods of Using Qiapine | 08-17-2017 |